Dare Bioscience
DARE
31 hedge funds and large institutions have $8.07M invested in Dare Bioscience in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 34 → 31 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
64% less capital invested
Capital invested by funds: $22.3M → $8.07M (-$14.2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$275K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$86.9K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$57.1K |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
+$56K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.9M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$954K |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$757K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$677K |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$104K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $3K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $2K | -$896 | -4 | -17% |
|
28
Walleye Trading
New York
| $1K | +$2.46K | +11 | New |
|
29
Simplex Trading
Chicago,
Illinois
| $1K | +$3.14K | +14 | New |
|
|
30
Fidelity Investments
Boston,
Massachusetts
| – | -$3.9M | -15,327 | Closed |
|
|
SFM
31
Sphera Funds Management
Tel Aviv,
Israel
| – | -$954K | -3,750 | Closed |
|
|
32
Principal Financial Group
Des Moines,
Iowa
| – | -$757K | -2,976 | Closed |
|
|
33
Alyeska Investment Group
Chicago,
Illinois
| – | -$677K | -2,661 | Closed |
|
34
Citadel Advisors
Miami,
Florida
| – | -$34K | -133 | Closed |
|
|
ARTA
35
A.R.T. Advisors
New York
| – | -$29K | -115 | Closed |
|
36
Millennium Management
New York
| – | -$23K | -90 | Closed |
|
|
BG
37
BlackRock Group
London,
United Kingdom
| – | -$8K | -32 | Closed |
|
38
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$4K | -17 | Closed |
|
DARE Hedge Fund Activity: Q3 2016 in Review
31 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q3 2016, worth a combined $8.07M — down 64% from $22.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of DARE and 6 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $275K. The largest seller was Fidelity Investments, exiting entirely with an estimated $3.9M sold.
- 31 institutional investors held Dare Bioscience (DARE) as of Q3 2016, down from 34 in Q2 2016.
- Funds reported $8.07M of Dare Bioscience stock for Q3 2016, down 64% quarter-over-quarter.
- 6 funds opened new Dare Bioscience positions in Q3 2016 and 9 closed out, a net change of -3 holders.
- The largest Dare Bioscience buyer in Q3 2016 was Jacobs Levy Equity Management, an estimated $275K added.
- The largest Dare Bioscience seller in Q3 2016 was Fidelity Investments, an estimated $3.9M sold.
Based on aggregated 13F filings for Q3 2016.